Tirzepatide is a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist approved in the United States for the treatment of type 2 diabetes, obesity, and obstructive sleep apnea. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.